肝纤维化无创评估进展
本文综述了肝纤维化无创检测(NITs)的现状与进展。简单血清学指标(如FIB-4、NFS)易获取但准确性低于复杂血清学指标(如透明质酸、III型胶原N端前肽);弹性成像(尤其磁共振弹性成像)准确性更高但受肥胖或成本限制。NITs适用于排除进展期纤维化或肝硬化,联合血清与弹性成像可提高诊断准确性,但尚不能准确反映治疗后的纤维化变化。
要点
- 慢性肝病患者均应评估肝纤维化,无创检测已常规用于专科实践。
- 简单血清学指标准确性低于复杂血清学指标和弹性成像。
- 联合血清与弹性成像可分别作为筛查和确认试验提高准确性。
核心结论
- 无创纤维化检测可用于排除进展期纤维化或肝硬化,但单独使用预测价值不足。
- 无创检测尚不能准确反映治疗后的纤维化变化,限制其疾病监测作用。
研究设计与样本
- 综述,系统汇总肝纤维化无创评估的现有方法及研究进展。
主要发现
- 简单血清学检测(如FIB-4、NFS)基于常规生化替代指标和临床危险因素,已在多种慢性肝病中广泛验证,但准确性低于复杂血清学检测。
- 复杂血清学检测纳入直接反映纤维化形成或降解的指标(如透明质酸、III型胶原N端前肽)。
- 弹性成像量化肝脏硬度作为纤维化标志物,准确性高于简单血清学检测,但随肥胖程度增加可靠性下降。
- 磁共振弹性成像比超声弹性成像更准确,且不受肥胖显著影响,但成本高、可及性有限。
- 脂质组学、蛋白质组学、肠道微生物组谱及microRNA特征是有前景的未来纤维化评估技术。
关键数值与推荐
- 简单血清学检测包括Fibrosis Score 4和NAFLD Fibrosis Score。
- 复杂血清学检测包括透明质酸和III型胶原N端前肽。
临床怎么用
- 对慢性肝病患者应评估肝纤维化以预测肝脏相关并发症风险并指导治疗、监测和随访。
- 联合使用血清学和弹性成像技术可分别作为筛查和确认试验以提高诊断准确性。
- 磁共振弹性成像适用于肥胖患者但需考虑成本和可及性。
局限性
- 无创检测尚未被证明能准确反映治疗后的纤维化变化。
- 简单血清学检测准确性低于复杂血清学检测和弹性成像。
- 超声弹性成像在肥胖患者中可靠性下降。
- 磁共振弹性成像成本高且可及性有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Liver fibrosis should be assessed in all individuals with chronic liver disease as it predicts the risk of future liver-related morbidity and thus need for treatment, monitoring and surveillance. Non-invasive fibrosis tests (NITs) overcome many limitations of liver biopsy and are now routinely incorporated into specialist clinical practice. Simple serum-based tests (eg, Fibrosis Score 4, non-alcoholic fatty liver disease Fibrosis Score) consist of readily available biochemical surrogates and clinical risk factors for liver fibrosis (eg, age and sex). These have been extensively validated across a spectrum of chronic liver diseases, however, tend to be less accurate than more 'complex' serum tests, which incorporate direct measures of fibrogenesis or fibrolysis (eg, hyaluronic acid, N-terminal propeptide of type three collagen). Elastography methods quantify liver stiffness as a marker of fibrosis and are more accurate than simple serum NITs, however, suffer increasing rates of unreliability with increasing obesity. MR elastography appears more accurate than sonographic elastography and is not significantly impacted by obesity but is costly with limited availability. NITs are valuable for excluding advanced fibrosis or cirrhosis, however, are not sufficiently predictive when used in isolation. Combining serum and elastography techniques increases diagnostic accuracy and can be used as screening and confirmatory tests, respectively. Unfortunately, NITs have not yet been demonstrated to accurately reflect fibrosis change in response to treatment, limiting their role in disease monitoring. However, recent studies have demonstrated lipidomic, proteomic and gut microbiome profiles as well as microRNA signatures to be promising techniques for fibrosis assessment in the future.
引用
- Loomba R, Adams LA. Advances in non-invasive assessment of hepatic fibrosis. Gut. 2020. PMID: 32066623. doi:10.1136/gutjnl-2018-317593
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。